Here a more detailed bio:
Ernest Mario grew up in Northern New Jersey, attending the Clifton Public Schools, elementary school #6, Christopher Columbus Middle School and Clifton High School.[2] He received a bachelor of science in Pharmacy from Rutgers University, and Masters and Ph.D. degrees in physical chemistry from the University of Rhode Island.[1] As a youth, Mario earned the rank of Eagle Scout in the Boy Scouts of America in 1954; he was awarded the Distinguished Eagle Scout Award in 2000 for his service to youth.[3]
Career in the pharmaceutical industry Edit
He was a registered pharmacist in the State of New York and worked as a community pharmacist during his early career. After completing his graduate work, he began a career in the pharmaceutical industry, beginning as a researcher for Strasenburgh Laboratories in Rochester, New York. He subsequently held positions with SmithKline & French in Philadelphia, PA; E.R. Squibb & Sons in New Brunswick, NJ and Princeton, NJ; and Glaxo Inc. in Research Triangle Park, NC. In 1990 he became the Chief Executive Officer of Glaxo Holdings, plc, based out of London, England. He served as Deputy Chairman of the Board and CEO of Glaxo Holdings from 1992 to 1993.[1] He was the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, in 2001. After Alza, Mario became Chairman and CEO of Reliant Pharmaceuticals, based in Liberty Corner, New Jersey. He was also the non-executive Chairman of Pharmaceutical Product Development, Inc, based in Wilmington, North Carolina, from 1993 to 2009.
In April 2010, Mario was appointed to the Board of Directors for Vivus Pharmaceuticals. Vivus is a biotechnology corporation based out of Mountain View, California. The US Food & Drug Administration recently approved the drugs Avanfil & Qsymia in April and June 2012 respectively. Avanfil is used in the treatment of erectile dysfunction and Qsymia is indicated for weight loss in obese patients.[4]
News 
Market Data 
Discover 
